Materias dentro de su búsqueda.
Mostrando 1,701 - 1,720 Resultados de 58,773 Para Buscar '"Her"', tiempo de consulta: 0.40s Limitar resultados
  1. 1701
    “…In this review, we present the clinical landscape of HER2-positive advanced BC and discuss our vision on how to tackle T-DXd resistance, providing a perspective on the priority areas of the cancer research in this setting.…”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Management of patients with HER2-positive metastatic breast cancer after trastuzumab deruxtecan failure
  2. 1702
    “…BACKGROUND: Among patients with human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (MBC), incidence of brain metastases (BMs) is relatively high and increasing. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Real-world outcomes among patients with HER2+ metastatic breast cancer with brain metastases
  3. 1703
    “…BACKGROUND: The frequency of HER2 overexpression in bladder cancer is reported as 9%-61%. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    HER2 Expression Associated with Clinical Characteristics and Prognosis of Urothelial Carcinoma in a Chinese Population
  4. 1704
    “…BACKGROUND: Thrombocytopenia is a common adverse event on HER2-targeted therapies, fam-trastuzumab deruxtecan (T-DXd) and ado-trastuzumab emtansine (T-DM1). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    HER2-targeted antibody–drug conjugates for breast cancer: ancestry and dose adjustment for thrombocytopenia
  5. 1705
    por Rousseau, G S
    Publicado 1997
    Enlace del recurso
    Texto
    The prospect before her: a history of women in western Europe, volume one, 1500–1800
  6. 1706
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Cutaneous Adnexal Adenocarcinoma: Genomic Analysis and Successful HER2-targeted Therapy of Metastatic Disease
  7. 1707
    “…Within HER2-low tumors, significant interpatient heterogeneity also exists in the hormone receptor–negative subgroup: basal-like tumors resemble HER2-0 disease, and non-basal-like HER2-low tumors mimic HER2-positive disease. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Molecular features and clinical implications of the heterogeneity in Chinese patients with HER2-low breast cancer
  8. 1708
    “…RESULTS: The ICERs of T-DXd vs. chemotherapy were $83,892/QALY, $82,808/QALY, and $93,358/QALY in all HER2-low advanced BC patients, HER2-positive (HER2+) advanced BC patients and HER2-negative (HER2-) advanced BC patients, respectively. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Cost-effectiveness of trastuzumab deruxtecan for previously treated HER2-low advanced breast cancer
  9. 1709
    “…Despite the OlympiA trial demonstrating that early-stage, high-risk, HER2- germline BRCA1 and BRCA2 mutation (gBRCAm) positive breast cancer patients can benefit from PARPi in the adjuvant setting, the gBRCA testing rate in early-stage HR+/HER2− patients remains suboptimal compared to that in early-stage TNBC patients. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Barriers to gBRCA Testing in High-Risk HER2-Negative Early Breast Cancer
  10. 1710
    “…Patients receiving neoadjuvant therapy (NAT) with dual HER2 blockade (trastuzumab and pertuzumab), followed by surgery, were included. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Anthracyclines versus No Anthracyclines in the Neoadjuvant Strategy for HER2+ Breast Cancer: Real-World Evidence
  11. 1711
    “…The efficacy of this virtual HER2 staining framework was demonstrated by quantitative analysis, in which three board-certified breast pathologists blindly graded the HER2 scores of virtually stained and immunohistochemically stained HER2 whole slide images (WSIs) to reveal that the HER2 scores determined by inspecting virtual IHC images are as accurate as their immunohistochemically stained counterparts. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Label-Free Virtual HER2 Immunohistochemical Staining of Breast Tissue using Deep Learning
  12. 1712
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Correction: Induction of phenotypic changes in HER2-postive breast cancer cells in vivo and in vitro
  13. 1713
    “…Here, we present the case of a 47-year-old woman diagnosed with luminal B breast cancer subtype and provide an in-depth analysis of her gene mutations, chromosomal alterations, mRNA and protein expression changes. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    A primary luminal/HER2 negative breast cancer patient with mismatch repair deficiency
  14. 1714
    “…Unfortunately, the use of subsequent HER2 targeted agents have not proven to be beneficial for HER2+ GC, although these agents are effective and currently being used for management of HER2+ breast cancer. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Synergistic Effects of Metformin and Trastuzumab on HER2 Positive Gastroesophageal Adenocarcinoma Cells In Vitro and In Vivo
  15. 1715
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Correction: PP2A inhibition overcomes acquired resistance to HER2 targeted therapy
  16. 1716
    “…Changes in the copy number aberration (CNA) landscape of luminal B HER2- negative (HER2−) breast cancer (BC) during anthracycline-based neoadjuvant chemotherapy (NAC) regimens were studied in order to identify groups of potential CNA markers of objective response and CNA markers for predicting the development of hematogenous metastasis. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    CNA Landscape of HER2-Negative Breast Cancer in Anthracycline-Based Neoadjuvant Chemotherapy Regimens
  17. 1717
    “…BACKGROUND: Broussonetia papyrifera (L.) L’Hér. ex Vent. has the characteristics of strong stress resistance, high crude protein content, and pruning tolerance. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Induction of tetraploids in Paper Mulberry (Broussonetia papyrifera (L.) L’Hér. ex Vent.) by colchicine
  18. 1718
    “…This retrospective study aimed to compare human epidermal growth factor receptor 2 (HER2)-low and HER2-0 breast cancers in hormone receptor (HR)-positive patients and investigate how it affect patients. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    The Impact of HER2-Low Expression on Oncologic Outcomes in Hormone Receptor-Positive Breast Cancer
  19. 1719
    “…BACKGROUND: The clinical benefit of determining the status of HER-2/neu amplification in breast cancer patients is well accepted. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Texto
    Real-time PCR complements immunohistochemistry in the determination of HER-2/neu status in breast cancer
  20. 1720
    “…BACKGROUND: HER2/neu overexpression is linked to promotion of angiogenesis in breast cancer. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Texto
    Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer
Herramientas de búsqueda: RSS